A large number of animal studies and clinical trials have been conducted employing IL-1-targeting drugs for cancer therapy against hematologic malignancies, non-small-cell lung cancer, metastatic breast cancer, colon cancer, pancreatic cancer, renal cell carcinoma, and melanoma [2,68,69], but not yet in bone sarcomas, with no trials underway (clinicaltrials.gov, accessed on 16 December 2023). The gene discussed is IL1B; the disease is bone sarcoma.